{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:46:57Z","timestamp":1792108017284,"version":"4.4.0"},"reference-count":233,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["HI23C0710"],"award-info":[{"award-number":["HI23C0710"]}]},{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["20210466"],"award-info":[{"award-number":["20210466"]}]},{"name":"Ministry of Oceans and Fisheries, Republic of Korea","award":["HI23C0710"],"award-info":[{"award-number":["HI23C0710"]}]},{"name":"Ministry of Oceans and Fisheries, Republic of Korea","award":["20210466"],"award-info":[{"award-number":["20210466"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Respiratory viral infections present significant global health challenges, causing substantial morbidity and mortality, particularly among highly susceptible components of the population. The emergence of pandemics and epidemics, such as those caused by influenza viruses and coronaviruses, emphasizes the urgent need for effective antiviral therapeutics. In this review, we explore the potential of broad-spectrum antiviral agents targeting respiratory RNA viruses, including influenza viruses, coronaviruses, respiratory syncytial virus, human metapneumovirus, human parainfluenza viruses, and rhinoviruses. Various broad-spectrum direct-acting and host-targeting antivirals are discussed, including monoclonal antibodies targeting conserved regions of viral surface proteins, molecules interfering with host cell receptors or viral replication machinery, viral protease inhibitors, siRNA therapies, ribonuclease, and 3D8 scFv. Advancements in host-targeting approaches to reduce resistance and RNA-based therapeutics offer significant potential for combating respiratory viral threats. Despite challenges, broad-spectrum antiviral agents represent a crucial strategy, particularly when specific viral pathogens are unidentified or rapid intervention is essential, such as during pandemics or outbreaks.<\/jats:p>","DOI":"10.3390\/ijms26041481","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:34:32Z","timestamp":1739252072000},"page":"1481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses"],"prefix":"10.3390","volume":"26","author":[{"given":"Quynh Xuan Thi","family":"Luong","sequence":"first","affiliation":[{"name":"Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4343-7475","authenticated-orcid":false,"given":"Phuong Thi","family":"Hoang","sequence":"additional","affiliation":[{"name":"Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Thi","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-1769","authenticated-orcid":false,"given":"Ramadhani Qurrota","family":"Ayun","sequence":"additional","affiliation":[{"name":"Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6090-507X","authenticated-orcid":false,"given":"Taek Kyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Risk Assessment Research Center, Korea Institute of Ocean Science & Technology, Geoje 53201, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9964-0176","authenticated-orcid":false,"given":"Sukchan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Huang, K., Ying, T., and Wu, Y. (2022). Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Viruses, 14.","DOI":"10.3390\/v14061162"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/microbiolspec.DMIH2-0028-2016","article-title":"Respiratory RNA Viruses","volume":"4","author":"Hodinka","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/vim.2022.0135","article-title":"Persistence of RNA Viruses in the Respiratory Tract: An Overview","volume":"36","year":"2023","journal-title":"Viral Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3201\/eid1201.051254","article-title":"Influenza Pandemics of the 20th Century","volume":"12","author":"Kilbourne","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_5","unstructured":"Jordan, E.O. (1927). Epidemic Influenza. A Survey, CABI Publishing."},{"key":"ref_6","first-page":"4","article-title":"The geography and mortality of the 1918 Influenza pandemic","volume":"65","author":"Patterson","year":"1991","journal-title":"Bull. Hist. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the Accounts: Global Mortality of the 1918\u20131920 \u201cSpanish\u201d Influenza Pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/aje\/kwy191","article-title":"Reassessing the Global Mortality Burden of the 1918 Influenza Pandemic","volume":"187","author":"Spreeuwenberg","year":"2018","journal-title":"Am. J. Epidemiology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1086\/511989","article-title":"The 1918 Influenza Pandemic: Insights for the 21st Century","volume":"195","author":"Morens","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_10","unstructured":"World Health Organization (2005). Report of the Review Committee on the Functioning of the International Health Regulations (2005) in Relation to Pandemic (H1N1) 2009, World Health Organization."},{"key":"ref_11","first-page":"E19","article-title":"The new pandemic influenza A\/(H1N1)pdm09 virus: Is it really \u201cnew\u201d?","volume":"57","author":"Baldo","year":"2016","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","unstructured":"Centers for Disease Control and Prevention (2024, September 12). 2009 H1N1 Pandemic (H1N1pdm09 virus), Available online: https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/flu\/pandemic-resources\/2009-h1n1-pandemic.html."},{"key":"ref_14","unstructured":"World Health Organization (2024, September 12). The Top 10 Causes of Death. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00431-013-2023-6","article-title":"The burden of seasonal and pandemic influenza in infants and children","volume":"173","author":"Ruf","year":"2014","journal-title":"Eur. J. Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e16861","DOI":"10.1097\/MD.0000000000016861","article-title":"Mortality risk factors in children with severe influenza virus infection admitted to the pediatric intensive care unit","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine"},{"key":"ref_18","unstructured":"World Health Organization (2024, October 01). Influenza (Seasonal). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0262-4079(20)30862-9","article-title":"An uncommon cold","volume":"246","author":"King","year":"2020","journal-title":"New. Sci."},{"key":"ref_20","unstructured":"Centers for Disease Control and Prevention (2024, October 01). National Trends for Common Human Coronaviruses, Available online: http:\/\/archive.cdc.gov\/#\/details?q=coronavirus%20national%20trends&start=0&rows=10&url=https:\/\/www.cdc.gov\/surveillance\/nrevss\/coronavirus\/natl-trends.html."},{"key":"ref_21","first-page":"21","article-title":"Epidemiology of COVID-19 in the Most Pandemic countries: A review article","volume":"9","author":"Harfouch","year":"2021","journal-title":"Acad J. Biotechnol."},{"key":"ref_22","unstructured":"World Health Organization (2024, October 01). WHO COVID-19 dashboard. 24. Available online: https:\/\/data.who.int\/dashboards\/covid19\/deaths."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hoang, P.T., Luong, Q.X.T., Ayun, R.Q., Lee, Y., Vo, T.T.B., Kim, T., and Lee, S. (2022). A Novel Approach of Antiviral Drugs Targeting Viral Genomes. Microorganisms, 10.","DOI":"10.3390\/microorganisms10081552"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Petrone-Garc\u00eda, V.M., Castellanos-Huerta, I., and Tellez-Isaias, G. (2023). Editorial: High-impact respiratory RNA virus diseases. Front. Veter-Sci., 10.","DOI":"10.3389\/fvets.2023.1273650"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI25669","article-title":"Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease","volume":"115","author":"Moscona","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105405","DOI":"10.1016\/j.antiviral.2022.105405","article-title":"Antiviral strategies against human metapneumovirus: Targeting the fusion protein","volume":"207","author":"Bergh","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12985-024-02327-9","article-title":"Epidemiology and diagnosis technologies of human metapneumovirus in China: A mini review","volume":"21","author":"Feng","year":"2024","journal-title":"Virol. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1093\/infdis\/jiad436","article-title":"Validity of clinical severity scores for respiratory syncytial virus: A systematic review","volume":"229","author":"Sheikh","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12098-023-04613-w","article-title":"Respiratory Syncytial Virus Infection: An Update","volume":"90","author":"Soni","year":"2023","journal-title":"Indian J. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0100822","DOI":"10.1128\/aac.01008-22","article-title":"Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection","volume":"66","author":"Guillon","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/CMR.00077-12","article-title":"Human Rhinoviruses","volume":"26","author":"Jacobs","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14787210.2017.1279970","article-title":"Antiviral therapy for respiratory viral infections in immunocompromised patients","volume":"15","author":"Shahani","year":"2017","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","article-title":"RNA virus mutations and fitness for survival","volume":"51","author":"Domingo","year":"1997","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2217\/fvl.14.41","article-title":"Variability in the Mutation Rates of RNA Viruses","volume":"9","author":"Combe","year":"2014","journal-title":"Futur. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: The epidemiology and management","volume":"ume 10","author":"Hussain","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s11845-021-02820-y","article-title":"Sars-Cov-2 and risk of antiviral drug resistance","volume":"191","author":"Vitiello","year":"2021","journal-title":"Ir. J. Med Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1038\/s41467-024-51924-3","article-title":"Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections","volume":"15","author":"Nooruzzaman","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Luong, Q.X.T., Hoang, P.T., Lee, Y., Ayun, R.Q., Na, K., Park, S., Lin, C., Lee, T.-K., and Lee, S. (2024). An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-52810-0"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12985-023-02198-6","article-title":"Multicenter analysis of epidemiological and clinical features of pediatric acute lower respiratory tract infections associated with common human coronaviruses in China, 2014\u20132019","volume":"20","author":"Han","year":"2023","journal-title":"Virol. J."},{"key":"ref_41","unstructured":"Centers for Disease Control and Prevention (2024, November 28). Types of COVID-19 Treatment, Available online: https:\/\/www.cdc.gov\/covid\/treatment\/index.html."},{"key":"ref_42","unstructured":"IDSA (2024, November 28). IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available online: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/#Recommendation:NeutralizingAntibodiesforProphylaxisPemivibart."},{"key":"ref_43","unstructured":"Centers for Disease Control and Prevention (2024, October 15). About Middle East Respiratory Syndrome (MERS), Available online: https:\/\/www.cdc.gov\/mers\/about\/."},{"key":"ref_44","unstructured":"World Health Organization (2024, September 20). Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/middle-east-respiratory-syndrome-coronavirus-(mers-cov)?gad_source=1&gclid=Cj0KCQiAo5u6BhDJARIsAAVoDWvUuypyq4b63a53x-w7cdQ2oSJC5OV4j_FSW3FaHuX2mf7QBUawDCIaApp1EALw_wcB."},{"key":"ref_45","unstructured":"Princeton BioMeditech (2024, November 28). STATUS\u2122 COVID-19\/FLU A&B May 2023, Available online: https:\/\/www.fda.gov\/media\/145696\/download."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","unstructured":"Centers for Disease Control and Prevention (2024, November 30). Treatment of Flu, Available online: https:\/\/www.cdc.gov\/flu\/treatment\/."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"G\u00e1lvez, N.M.S., Andrade, C.A., Pacheco, G.A., Soto, J.A., Stranger, V., Rivera, T., V\u00e1squez, A.E., and Kalergis, A.M. (2021). Host Components That Modulate the Disease Caused by hMPV. Viruses, 13.","DOI":"10.3390\/v13030519"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Soto, J.A., G\u00e1lvez, N.M.S., Benavente, F.M., Pizarro-Ortega, M.S., Lay, M.K., Riedel, C., Bueno, S.M., Gonzalez, P.A., and Kalergis, A.M. (2018). Human Metapneumovirus: Mechanisms and Molecular Targets Used by the Virus to Avoid the Immune System. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02466"},{"key":"ref_50","unstructured":"Centers for Disease Control and Prevention (2024, September 18). Human Metapneumovirus (HMPV) National Trends, Available online: https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/surveillance\/nrevss\/hmpv\/natl-trend.html."},{"key":"ref_51","unstructured":"Centers for Disease Control and Prevention (2024, September 18). About Human Metapneumovirus, Available online: https:\/\/www.cdc.gov\/human-metapneumovirus\/about\/."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104261","DOI":"10.1016\/j.jcv.2020.104261","article-title":"Human parainfluenza virus circulation, United States, 2011-2019","volume":"124","author":"DeGroote","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_53","unstructured":"Centers for Disease Control and Prevention (2024, September 12). Clinical Overview of Human Parainfluenza Viruses (HPIVs), Available online: https:\/\/www.cdc.gov\/parainfluenza\/hcp\/clinical-overview\/."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"105734","DOI":"10.1016\/j.antiviral.2023.105734","article-title":"Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication","volume":"219","author":"Luganini","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_55","unstructured":"Centers for Disease Control and Prevention (2024, September 12). RSV National Trends, Available online: https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/surveillance\/nrevss\/rsv\/natl-trend.html."},{"key":"ref_56","unstructured":"Bhatia, R. (2024, September 15). Respiratory Syncytial Virus (RSV) and Human Metapneumovirus Infections. Available online: https:\/\/www.msdmanuals.com\/professional\/pediatrics\/respiratory-disorders-in-young-children\/respiratory-syncytial-virus-rsv-and-human-metapneumovirus-infections."},{"key":"ref_57","unstructured":"Centers for Disease Control and Prevention (2024, October 01). Symptoms and Care of RSV, Available online: https:\/\/www.cdc.gov\/rsv\/symptoms\/index.html."},{"key":"ref_58","unstructured":"Service, N.H. (2024, September 12). Respiratory Syncytial Virus (RSV). Available online: https:\/\/www.nhs.uk\/conditions\/respiratory-syncytial-virus-rsv\/."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12931-019-1120-0","article-title":"Rhinovirus replication and innate immunity in highly differentiated human airway epithelial cells","volume":"20","author":"Warner","year":"2019","journal-title":"Respir. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kenmoe, S., Kengne-Nde, C., Ebogo-Belobo, J.T., Mbaga, D.S., Modiyinji, A.F., and Njouom, R. (2020). Systematic review and meta-analysis of the prevalence of common respiratory viruses in children <2 years with bronchiolitis in the pre-COVID-19 pandemic era. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0242302"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e2365","DOI":"10.1002\/rmv.2365","article-title":"Respiratory viral co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-analysis","volume":"33","author":"Krumbein","year":"2022","journal-title":"Rev. Med Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2352-4642(22)00092-X","article-title":"Prevalence of respiratory viruses in community-acquired pneumonia in children: A systematic review and meta-analysis","volume":"6","author":"Pratt","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ljubin-Sternak, S. (2023). and T. Me\u0161trovi\u0107, Rhinovirus\u2014A True Respiratory Threat or a Common Inconvenience of Childhood?. Viruses, 15.","DOI":"10.3390\/v15040825"},{"key":"ref_64","unstructured":"Centers for Disease Control and Prevention (2024, September 12). About Rhinoviruses, Available online: https:\/\/www.cdc.gov\/rhinoviruses\/about\/index.html."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1055\/s-0036-1584803","article-title":"Antivirals for Respiratory Viral Infections: Problems and Prospects","volume":"37","author":"Liu","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Vardanyan, R., and Hruby, V. (2016). Antiviral Drugs. Synthesis of Best Seller Drugs, Academic Press.","DOI":"10.1016\/B978-0-12-411492-0.00034-1"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Prada, L.S.-D., Sanz-Mu\u00f1oz, I., Sun, W., Palese, P., de Lejarazu, R.O., Eiros, J.M., Garc\u00eda-Sastre, A., and Aydillo, T. (2023). Group 1 and group 2 hemagglutinin stalk antibody response according to age. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1194073"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2020.10.009","article-title":"Advances in the development of entry inhibitors for sialic-acid-targeting viruses","volume":"26","author":"Heida","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Yi, K.S., Choi, J.-A., Kim, P., Ryu, D.-K., Yang, E., Son, D., Shin, J., Park, H., Lee, S., and Lee, H. (2020). Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236172"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e4260","DOI":"10.1093\/cid\/ciaa1725","article-title":"Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model","volume":"73","author":"Han","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody Recognition of a Highly Conserved Influenza Virus Epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L.L.M., Alard, P., Cornelissen, L., Bakker, A., Cox, F., Van Deventer, E., and Guan, Y. (2008). Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003942"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1021\/acs.biochem.1c00551","article-title":"Stability of HA2 Prefusion Structure and pH-Induced Conformational Changes in the HA2 Domain of H3N2 Hemagglutinin","volume":"60","author":"Eller","year":"2021","journal-title":"Biochemistry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"eaar6221","DOI":"10.1126\/science.aar6221","article-title":"A small-molecule fusion inhibitor of influenza virus is orally active in mice","volume":"363","author":"Kadam","year":"2019","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly Conserved Protective Epitopes on Influenza B Viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cui, W., Wang, K., Ruan, J., Qi, Z., Feng, Y., Shao, Y., and Tuszynski, J.A. (2012). The Molecular Mechanism of Action of the CR6261-Azichromycin Combination Found through Computational Analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037790"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/jix292","article-title":"The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses","volume":"216","author":"Lakdawala","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"104763","DOI":"10.1016\/j.antiviral.2020.104763","article-title":"Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study","volume":"184","author":"Sloan","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1016\/j.ymthe.2024.07.023","article-title":"Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity","volume":"32","author":"Moirangthem","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-018-03665-3","article-title":"How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin","volume":"9","author":"Doud","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/s41591-020-0937-x","article-title":"Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model","volume":"26","author":"Park","year":"2020","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Lim, K.K., Ng, K., Balachandran, S., Russell, M.D., Boalch, A., Sinclair, A., Coker, B., Vinnakota, K., Mansoor, R., and Douiri, A. (2023). Measuring the impact of monoclonal antibody therapies. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1256712"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","first-page":"15","article-title":"Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181","volume":"66","author":"Sanders","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.antiviral.2013.04.012","article-title":"The use of sialidase therapy for respiratory viral infections","volume":"98","author":"Nicholls","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1093\/cid\/ciab113","article-title":"DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study","volume":"73","author":"Chemaly","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Triana-Baltzer, G.B., Gubareva, L.V., Klimov, A.I., Wurtman, D.F., Moss, R.B., Hedlund, M., Larson, J.L., Belshe, R.B., and Fang, F. (2009). Inhibition of Neuraminidase Inhibitor-Resistant Influenza Virus by DAS181, a Novel Sialidase Fusion Protein. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007838"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection","volume":"206","author":"Moss","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_91","unstructured":"(2024, September 12). ClinicalTrials.gov. A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01644877?term=DAS181&draw=2&rank=4."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12879-020-05698-w","article-title":"Effect of Arbidol (Umifenovir) on COVID-19: A randomized controlled trial","volume":"20","author":"Nojomi","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Leneva, I., Kartashova, N., Poromov, A., Gracheva, A., Korchevaya, E., Glubokova, E., Borisova, O., Shtro, A., Loginova, S., and Shchukina, V. (2021). Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses, 13.","DOI":"10.3390\/v13081665"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: An update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00063198-200405000-00009","article-title":"Antiviral chemotherapeutic agents against respiratory viruses: Where are we now and what\u2019s in the pipeline?","volume":"10","author":"Brooks","year":"2004","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jmv.22234","article-title":"Antiviral Activity of Arbidol, a Broad-Spectrum Drug for Use Against Respiratory Viruses, Varies According to Test Conditions","volume":"84","author":"Brooks","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/aps.2013.54","article-title":"Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection","volume":"34","author":"Liu","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijid.2018.11.257","article-title":"Umifenovir in treatment of influenza and acute respiratory viral infections in outpatient care","volume":"79","author":"Pshenichnaya","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: A retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yang, C., Ke, C., Yue, D., Li, W., Hu, Z., Liu, W., Hu, S., Wang, S., and Liu, J. (2020). Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals. Front. Public Health, 8.","DOI":"10.3389\/fpubh.2020.00249"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/jmv.25358","article-title":"Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study","volume":"91","author":"Leneva","year":"2018","journal-title":"J. Med Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3892\/etm.2022.11672","article-title":"A systematic review and meta-analysis of Arbidol therapy for acute respiratory viral infections: A potential treatment for COVID-19","volume":"24","author":"Feng","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jmv.26256","article-title":"Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis","volume":"93","author":"Huang","year":"2020","journal-title":"J. Med Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1038\/s41598-021-88886-1","article-title":"Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo","volume":"11","author":"Song","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","article-title":"Aprotinin and similar protease inhibitors as drugs against influenza","volume":"92","author":"Zhirnov","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01309780","article-title":"Replication of Influenza B virus in chicken embryos is suppressed by exogenous aprotinin","volume":"135","author":"Zhirnov","year":"1994","journal-title":"Arch. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Ivachtchenko, A.V., Ivashchenko, A.A., Shkil, D.O., and Ivashchenko, I.A. (2023). Aprotinin\u2014Drug against Respiratory Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311173"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e13776","DOI":"10.1111\/eci.13776","article-title":"Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19","volume":"52","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e13850","DOI":"10.1111\/eci.13850","article-title":"Inhaled aprotinin reduces viral load in mild-to-moderate inpatients with SARS-CoV-2 infection","volume":"52","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1128\/JVI.75.19.9297-9301.2001","article-title":"Plasminogen-Binding Activity of Neuraminidase Determines the Pathogenicity of Influenza A Virus","volume":"75","author":"Goto","year":"2001","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pupt.2015.07.001","article-title":"The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells","volume":"33","author":"Yamaya","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Bojkova, D., Bechtel, M., McLaughlin, K.-M., McGreig, J.E., Klann, K., Bellinghausen, C., Rohde, G., Jonigk, D., Braubach, P., and Ciesek, S. (2020). Aprotinin Inhibits SARS-CoV-2 Replication. Cells, 9.","DOI":"10.3390\/cells9112377"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41392-021-00740-y","article-title":"ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41564-023-01389-9","article-title":"Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies","volume":"8","author":"Zhang","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_115","first-page":"935","article-title":"Kinase Inhibitors as Underexplored Antiviral Agents","volume":"65","author":"Caballero","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Logue, J., Chakraborty, A.R., Johnson, R., Goyal, G., Rodas, M., Taylor, L.J., Baracco, L., McGrath, M.E., Haupt, R., and Furlong, B.A. (2022). PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03766-2"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1247\/csf.17003","article-title":"PI5P and PI(3,5)P2: Minor, but Essential Phosphoinositides","volume":"42","author":"Hasegawa","year":"2017","journal-title":"Cell Struct. Funct."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41392-022-01025-8","article-title":"PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron","volume":"7","author":"Su","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.embor.7400243","article-title":"The small chemical vacuolin\u20131 inhibits Ca2+ dependent lysosomal exocytosis but not cell resealing","volume":"5","author":"Cerny","year":"2004","journal-title":"EMBO Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/ncb1269","article-title":"Endosome-to-cytosol transport of viral nucleocapsids","volume":"7","author":"Luyet","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e0105023","DOI":"10.1128\/aac.01050-23","article-title":"Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice","volume":"68","author":"Baker","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1038\/s41467-020-17986-9","article-title":"A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Zhao, H., Zhou, J., Zhang, K., Chu, H., Liu, D., Poon, V.K.-M., Chan, C.C.-S., Leung, H.-C., Fai, N., and Lin, Y.-P. (2016). A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci. Rep., 6.","DOI":"10.1038\/srep22008"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/emboj.2011.286","article-title":"Endosome maturation","volume":"30","author":"Huotari","year":"2011","journal-title":"EMBO J."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Offermanns, S., and Rosenthal, W. (2020). Viral Proteases. Encyclopedia of Molecular Pharmacology, Springer International Publishing.","DOI":"10.1007\/978-3-030-21573-6"},{"key":"ref_126","unstructured":"Cameron, C.E., Arnold, J.J., and Kaguni, L.S. (2021). Chapter Nine\u2014Viral proteases: Structure, mechanism and inhibition. The Enzymes, Academic Press."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/CMR.11.4.614","article-title":"Protease Inhibitors as Antiviral Agents","volume":"11","author":"Patick","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1021\/acsptsci.2c00206","article-title":"Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies","volume":"6","author":"Dampalla","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-022-29413-2","article-title":"Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014Drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1021\/cb500917m","article-title":"Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV","volume":"10","author":"Lee","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jmb.2011.09.030","article-title":"Comparison of SARS and NL63 Papain-Like Protease Binding Sites and Binding Site Dynamics: Inhibitor Design Implications","volume":"414","author":"Chaudhuri","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Mengist, H.M., Dilnessa, T., and Jin, T. (2021). Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.622898"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Chan, S.-W. (2020). Current and Future Direct-Acting Antivirals Against COVID-19. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.587944"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"m2650","DOI":"10.1136\/bmj.m2650","article-title":"COVID-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds","volume":"370","author":"Griffin","year":"2020","journal-title":"BMJ"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","article-title":"Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms","volume":"59","author":"Nutho","year":"2020","journal-title":"Biochemistry"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Yu, W., Wu, X., Zhao, Y., Chen, C., Yang, Z., Zhang, X., Ren, J., Wang, Y., Wu, C., and Li, C. (2021). Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules, 26.","DOI":"10.3390\/molecules26237385"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014A possible reference for coronavirus disease-19 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"J. Med Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jtbi.2008.07.030","article-title":"Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors","volume":"254","author":"Nukoolkarn","year":"2008","journal-title":"J. Theor. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture","volume":"58","author":"Jochmans","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with Lopinavir\/Ritonavir or Interferon-\u03b21b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"105766","DOI":"10.1016\/j.antiviral.2023.105766","article-title":"Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro","volume":"221","author":"Gallucci","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment With Lopinavir\/Ritonavir or Interferon-\u03b21b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"105555","DOI":"10.1016\/j.antiviral.2023.105555","article-title":"Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses","volume":"211","author":"Li","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"eabq7360","DOI":"10.1126\/scitranslmed.abq7360","article-title":"SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376","volume":"15","author":"Heilmann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"COVID-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamainternmed.2024.2007","article-title":"Nirmatrelvir-Ritonavir and Symptoms in Adults with Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial","volume":"184","author":"Geng","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2246594","DOI":"10.1080\/22221751.2023.2246594","article-title":"A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants","volume":"12","author":"Worrall","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430\u2014A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Heal."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"105180","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1099\/0022-1317-83-12-2983","article-title":"Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts","volume":"83","author":"Gribaudo","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.1500","article-title":"Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy","volume":"26","author":"Munger","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.abb.2017.06.019","article-title":"The dihydroorotate dehydrogenases: Past and present","volume":"632","author":"Reis","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/15257770.2020.1723625","article-title":"The pathway to pyrimidines: The essential focus on dihydroorotate dehydrogenase, the mitochondrial enzyme coupled to the respiratory chain","volume":"39","author":"Carrey","year":"2020","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Sibille, G., Luganini, A., Sainas, S., Boschi, D., Lolli, M.L., and Gribaudo, G. (2022). The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis. Viruses, 14.","DOI":"10.3390\/v14102281"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Calistri, A., Luganini, A., Mognetti, B., Elder, E., Sibille, G., Conciatori, V., Del Vecchio, C., Sainas, S., Boschi, D., and Montserrat, N. (2021). The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses. Microorganisms, 9.","DOI":"10.3390\/microorganisms9081731"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/21505594.2021.1871823","article-title":"Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses","volume":"12","author":"Li","year":"2021","journal-title":"Virulence"},{"key":"ref_164","first-page":"1473","article-title":"Inhibition of RNA synthesis and reproduction of tick-encephalitis virus under the influence of ribonuclease","volume":"180","author":"Salganik","year":"1968","journal-title":"Dokl. Akad. Nauk. SSSR"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"15442","DOI":"10.3390\/ijms160715442","article-title":"Eosinophil-Derived Neurotoxin (EDN\/RNase 2) and the Mouse Eosinophil-Associated RNases (mEars): Expanding Roles in Promoting Host Defense","volume":"16","author":"Rosenberg","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1086\/515322","article-title":"Recombinant Human Eosinophil-Derived Neurotoxin\/RNase 2 Functions as an Effective Antiviral Agent against Respiratory Syncytial Virus","volume":"177","author":"Domachowske","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1128\/JVI.02953-14","article-title":"RNase L Targets Distinct Sites in Influenza A Virus RNAs","volume":"89","author":"Cooper","year":"2015","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"25601","DOI":"10.1074\/jbc.M200211200","article-title":"2\u2032-5\u2032 Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells","volume":"277","author":"Behera","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e00319-19","DOI":"10.1128\/mBio.00319-19","article-title":"Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection","volume":"10","author":"Comar","year":"2019","journal-title":"mBio"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12668-016-0341-7","article-title":"A Novel Antiviral Strategy against MERS-CoV and HCoV-229E Using Binase to Target Viral Genome Replication","volume":"7","author":"Ulyanova","year":"2017","journal-title":"Bionanoscience"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Shah Mahmud, R., M\u00fcller, C., Romanova, Y., Mostafa, A., Ulyanova, V., Pleschka, S., and Ilinskaya, O. (2017). Ribonuclease from Bacillus Acts as an Antiviral Agent against Negative- and Positive-Sense Single Stranded Human Respiratory RNA Viruses. BioMed Res. Int., 2017.","DOI":"10.1155\/2017\/5279065"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2001650","DOI":"10.1002\/adhm.202001650","article-title":"siRNA Therapeutics against Respiratory Viral Infections\u2014What Have We Learned for Potential COVID-19 Therapies?","volume":"10","author":"Mehta","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jconrel.2022.03.051","article-title":"Inhibition of SARS-CoV-2 replication in the lung with siRNA\/VIPER polyplexes","volume":"345","author":"Baldassi","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm1164","article-title":"Inhibition of respiratory viruses by nasally administered siRNA","volume":"11","author":"Bitko","year":"2004","journal-title":"Nat. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.15252\/emmm.202115298","article-title":"A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant","volume":"14","author":"Chang","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/microbiolres14040116","article-title":"Evaluation of Predicted siRNA as an Antiviral against MERS-CoV Targeting the Membrane Gene in the Vero Cell Line","volume":"14","author":"Shehata","year":"2023","journal-title":"Microbiol. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.antiviral.2007.12.010","article-title":"PA subunit of RNA polymerase as a promising target for anti-influenza virus agents","volume":"78","author":"Nakazawa","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.cr.7290286","article-title":"Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs","volume":"15","author":"Shi","year":"2005","journal-title":"Cell Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1385\/MB:33:2:141","article-title":"Identification of Effective siRNA Blocking the Expression of SARS Viral Envelope E and RDRP Genes","volume":"33","author":"Meng","year":"2006","journal-title":"Mol. Biotechnol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3390\/v2071448","article-title":"siRNA for Influenza Therapy","volume":"2","author":"Barik","year":"2010","journal-title":"Viruses"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e01916-18","DOI":"10.1128\/JVI.01916-18","article-title":"Efficient Inhibition of Avian and Seasonal Influenza A Viruses by a Virus-Specific Dicer-Substrate Small Interfering RNA Swarm in Human Monocyte-Derived Macrophages and Dendritic Cells","volume":"93","author":"Jiang","year":"2019","journal-title":"J. Virol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","article-title":"Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)","volume":"77","author":"DeVincenzo","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/AAC.00014-09","article-title":"RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy","volume":"53","author":"Alvarez","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1164\/rccm.201009-1488ED","article-title":"RNA interference, RSV, and lung transplantation: A promising future for siRNA therapeutics","volume":"183","author":"Astor","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","article-title":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients","volume":"35","author":"Gottlieb","year":"2016","journal-title":"J. Hear. Lung Transplant."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.healun.2009.11.048","article-title":"41: Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV)","volume":"29","author":"Zamora","year":"2010","journal-title":"J. Hear. Lung Transplant."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1073\/pnas.0437841100","article-title":"RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription","volume":"100","author":"Ge","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.4142\/jvs.21174","article-title":"Improving siRNA design targeting nucleoprotein gene as antiviral against the Indonesian H5N1 virus","volume":"23","author":"Hartawan","year":"2022","journal-title":"J. Veter- Sci."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1128\/AAC.02768-13","article-title":"Targeted Small Interfering RNA-Immunoliposomes as a Promising Therapeutic Agent against Highly Pathogenic Avian Influenza A (H5N1) Virus Infection","volume":"58","author":"Khantasup","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13568-016-0187-y","article-title":"Inhibiting avian influenza virus shedding using a novel RNAi antiviral vector technology: Proof of concept in an avian cell model","volume":"6","author":"Linke","year":"2016","journal-title":"AMB Express"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1073\/pnas.0402630101","article-title":"Protection against lethal influenza virus challenge by RNA interference in vivo","volume":"101","author":"Tompkins","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Friedrich, M., Pfeifer, G., Binder, S., Aigner, A., Vollmer Barbosa, P., Makert, G.R., Fertey, J., Ulbert, S., Bodem, J., and K\u00f6nig, E.-M. (2022). Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.801870"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jconrel.2014.06.009","article-title":"Quo vadis polyplex?","volume":"190","author":"Merkel","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1021\/ar200110p","article-title":"Nonviral Pulmonary Delivery of siRNA","volume":"45","author":"Merkel","year":"2011","journal-title":"Accounts Chem. Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ymthe.2006.01.001","article-title":"Progress towards in Vivo Use of siRNAs","volume":"13","author":"Behlke","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"15287","DOI":"10.1074\/jbc.M600937200","article-title":"Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity","volume":"281","author":"Kim","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Hoang, P.T., Luong, Q.X.T., Ayun, R.Q., Lee, Y., Oh, K.-J., Kim, T., Lee, T.-K., and Lee, S. (2024). A synergistic therapy against influenza virus A\/H1N1\/PR8 by a HA1 specific neutralizing single-domain VL and an RNA hydrolyzing scFv. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1355599"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Lee, Y., Hoang, P.T., Kim, D., Ayun, R.Q., Luong, Q.X.T., Na, K., Kim, T., Oh, Y., Kim, W.-K., and Lee, S. (2022). A Therapeutically Active Minibody Exhibits an Antiviral Activity in Oseltamivir-Resistant Influenza-Infected Mice via Direct Hydrolysis of Viral RNAs. Viruses, 14.","DOI":"10.3390\/v14051105"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1081\/IMM-120016241","article-title":"Production and characterization of an anti-idiotypic single chain Fv that recognizes an anti-DNA antibody","volume":"31","author":"Kwon","year":"2002","journal-title":"Immunol. Investig."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00299-009-0758-3","article-title":"Production of recombinant single chain antibodies (scFv) in vegetatively reproductive Kalanchoe pinnata by in planta transformation","volume":"28","author":"Jung","year":"2009","journal-title":"Plant Cell Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1007\/s00253-014-6257-7","article-title":"Development of Lactobacillus paracasei harboring nucleic acid-hydrolyzing 3D8 scFv as a preventive probiotic against murine norovirus infection","volume":"99","author":"Hoang","year":"2014","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"14373","DOI":"10.1038\/s41598-017-14793-z","article-title":"Heparan sulfate proteoglycans (HSPGs) and chondroitin sulfate proteoglycans (CSPGs) function as endocytic receptors for an internalizing anti-nucleic acid antibody","volume":"7","author":"Park","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00018-009-9179-2","article-title":"A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity","volume":"66","author":"Jang","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.3390\/v7092863","article-title":"Preventive Activity against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice","volume":"7","author":"Cho","year":"2015","journal-title":"Viruses"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Kumari, R., Sharma, S.D., Kumar, A., Ende, Z., Mishina, M., Wang, Y., Falls, Z., Samudrala, R., Pohl, J., and Knight, P.R. (2023). Antiviral Approaches against Influenza Virus. Clin. Microbiol. Rev., 36.","DOI":"10.1128\/cmr.00040-22"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/13543776.2020.1831471","article-title":"Searching for effective antiviral small molecules against influenza A virus: A patent review","volume":"31","author":"Ginex","year":"2020","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: Towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-019-0567-0","article-title":"Development of effective anti-influenza drugs: Congeners and conjugates\u2014A review","volume":"26","author":"Shie","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Maffei, M.E., Salata, C., and Gribaudo, G. (2022). Tackling the Future Pandemics: Broad-Spectrum Antiviral Agents (BSAAs) Based on A-Type Proanthocyanidins. Molecules, 27.","DOI":"10.3390\/molecules27238353"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1039\/C4NP00085D","article-title":"Antiviral drug discovery: Broad-spectrum drugs from nature","volume":"32","author":"Martinez","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: The example of cyclophilin inhibitors","volume":"99","author":"Lin","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2012.09.022","article-title":"Host-targeting agents for prevention and treatment of chronic hepatitis C\u2014Perspectives and challenges","volume":"58","author":"Zeisel","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0140-6736(00)02388-6","article-title":"Hit HIV-1 hard, but only when necessary","volume":"355","author":"Harrington","year":"2000","journal-title":"Lancet"},{"key":"ref_220","first-page":"790","article-title":"Combination Drug for HCV Infection","volume":"318","author":"Voelker","year":"2017","journal-title":"JAMA"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1002\/jmv.28037","article-title":"Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study","volume":"94","author":"Kojima","year":"2022","journal-title":"J. Med Virol."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Chatterjee, B., and Thakur, S.S. (2022). Remdesivir and Its Combination with Repurposed Drugs as COVID-19 Therapeutics. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.830990"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.metop.2021.100096","article-title":"Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic","volume":"10","author":"Vallianou","year":"2021","journal-title":"Metab. Open"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/IJGM.S283910","article-title":"Drug\u2013Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C","volume":"ume 14","author":"Gao","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Duval, X., van der Werf, S., Blanchon, T., Mosnier, A., Bouscambert-Duchamp, M., Tibi, A., Enouf, V., Charlois-Ou, C., Vincent, C., and Andreoletti, L. (2010). Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial. PLoS Med., 7.","DOI":"10.1371\/annotation\/ca448e7c-fbbc-43e9-9981-108c9bfa8bce"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"105571","DOI":"10.1016\/j.ijantimicag.2018.10.014","article-title":"Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection","volume":"56","author":"Solas","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1038\/ncomms8708","article-title":"A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus","volume":"6","author":"Wu","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_228","unstructured":"National Center for Biotechnology Information (2024) (2024, May 07). PubChem Compound Summary for CID 131411, Arbidol, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Arbidol."},{"key":"ref_229","unstructured":"National Center for Biotechnology Information (2024) (2024, May 07). PubChem Compound Summary for CID 16130295, Trasylol, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Trasylol."},{"key":"ref_230","unstructured":"National Center for Biotechnology Information (2024) (2024, May 07). PubChem Compound Summary for CID 10173277, Apilimod, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Apilimod."},{"key":"ref_231","unstructured":"National Center for Biotechnology Information (2024) (2024, May 07). PubChem Compound Summary for CID 92727, Lopinavir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lopinavir."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molcel.2013.12.025","article-title":"Dimeric Structure of Pseudokinase RNase L Bound to 2-5A Reveals a Basis for Interferon-Induced Antiviral Activity","volume":"53","author":"Huang","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7831\/ras.7.10","article-title":"Systemic Delivery of Small Interfering RNA Therapeutics: Obstacles and Advances","volume":"7","author":"Chandela","year":"2019","journal-title":"Rev. Agric. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:30:46Z","timestamp":1760027446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":233,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26041481"],"URL":"https:\/\/doi.org\/10.3390\/ijms26041481","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}